# Anti-Retroviral Therapy (ART)

> Anti-retroviral therapy is the cornerstone of HIV treatment, aimed at reducing viral load, maintaining immune function, and preventing HIV-related complications and transmission.

## Classes of Anti-Retroviral Drugs

### 1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

- **Mechanism of Action**: Inhibit HIV reverse transcriptase by incorporating into the viral DNA chain, causing termination.
- **Examples**: `Zidovudine` (AZT), `Lamivudine` (3TC), `Tenofovir` (TDF), `Emtricitabine` (FTC).
- **Side Effects**:
  - Lactic acidosis
  - Hepatomegaly with steatosis [^1]
  - Bone marrow suppression (`Zidovudine`)
  - Renal toxicity (`Tenofovir`)

[^1]: **Steatosis**: fat buildup in an organ (usually your liver)

### 2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

- **Mechanism of Action**: Bind to and inhibit HIV reverse transcriptase at a different site from NRTIs.
- **Examples**: `Efavirenz` (EFV), `Nevirapine` (NVP), `Etravirine` (ETR).
- **Side Effects**
  - Rash
  - Hepatotoxicity
  - Neuropsychiatric symptoms (`Efavirenz`)

### 3. Protease Inhibitors (PIs)

- **Mechanism of Action**: Inhibit HIV protease, preventing the cleavage of viral polyproteins, leading to the production of immature, non-infectious viral particles.
- **Examples**: `Lopinavir/ritonavir` (LPV/r), `Atazanavir` (ATV), `Darunavir` (DRV).
- **Side Effects**:
  - Gastrointestinal disturbances
  - Hyperlipidemia (**PI** to _Lipid_ and _Insulin_)
  - Insulin resistance
  - Lipodystrophy
  - Hepatotoxicity

### 4. Integrase Strand Transfer Inhibitors (INSTIs)

- **Mechanism of Action**: Inhibit HIV integrase, preventing the integration of viral DNA into the host genome.
- **Examples**: `Raltegravir` (RAL), `Elvitegravir` (EVG), `Dolutegravir` (DTG).
- **Side Effects**:
  - Insomnia (**INS**TI to _**Ins**omnia_)
  - Headache
  - Weight gain
  - Hypersensitivity (Rare)

### 5. Entry Inhibitors

#### Fusion Inhibitors

- **Mechanism of Action**: Inhibit fusion of HIV with the host cell membrane.
- **Examples**: `Enfuvirtide` (T20) (**En**try + **Fu**sion + **Vir**us + **Tide** â†’ `Enfuvirtide`)
- **Side Effects**: Injection site reactions, bacterial pneumonia.

#### CCR5 Antagonists

- **Mechanism of Action**: Block the CCR5 co-receptor on host cells, preventing HIV entry.
- **Examples**: `Maraviroc` (MVC).
- **Side Effects**:
  - Hepatotoxicity
  - Orthostatic hypotension (Postural hypotension)
  - Cough
  - Upper respiratory infections

## Combination Therapy

### Highly Active Anti-Retroviral Therapy (HAART)

- **Approach**: Combining drugs from different classes to enhance efficacy and reduce the likelihood of resistance.
- **Common Regimens**:
  - Two NRTIs + One NNRTI
  - Two NRTIs + One PI (boosted with `ritonavir` or `cobicistat`)
  - Two NRTIs + One INSTI

## Treatment Goals

- **Viral Suppression**: Reduce plasma HIV RNA to undetectable levels.
- **Immune Restoration**: Increase CD4+ T-cell count.
- **Prevent Opportunistic Infections**: Maintain immune function.
- **Reduce HIV Transmission**: Lowering viral load reduces the risk of transmission.

## Monitoring and Follow-Up

- **Viral Load Testing**: Regularly to ensure effective viral suppression.
- **CD4 Count**: To monitor immune status.
- **Resistance Testing**: If treatment failure is suspected.
- **Adherence**: Ensure patient adherence to therapy to prevent resistance.

## Side Effects and Management

- **Short-Term Side Effects**: GI upset, headache, fatigue, which often improve over time.
- **Long-Term Side Effects**: Metabolic complications, cardiovascular disease, renal and hepatic toxicity, requiring regular monitoring and management.

---
